Yesterday, we organized a Scientific Advisory Meeting with some high-class experts in the field of C1q. We had a great discussion and brainstorm session on the future of Montis Biosciences. Let's bring this future to life! Thank you Prof. Dr. Erik Hack, Prof. Dr. Andrea Tenner, Prof. Dr. Moh Daha, Prof. Dr. Tom Eirik Mollnes & Prof. Dr. Thomas Sharp for your valuable contributions. Gil Beyen, Carol Walton, PhD, Mo Benkheil, PhD, Andrea Casazza, Iman El-Hariry, Celia Luchena Moreno, PhD, Madryn Lake, Nathan Reynders, Ward Celus, Lawrence Van Helleputte Venue: Faculty Club Leuven
Montis Biosciences
Biotechnology Research
Heverlee, Flemish Region 1,401 followers
Pioneering next generation therapeutics to treat severe, chronic inflammation-driven diseases.
About us
Montis Biosciences is a preclinical-stage biopharmaceutical company advancing innovative therapeutics to treat inflammation-driven neurodegenerative diseases, autoimmune disorders and selected cancers. Leveraging its patient-centric discovery platform, Montis is advancing unique and potent antibodies to bring new treatment options to those patients. Montis’ lead program, MB01, focuses on modulating the multifaceted roles of C1q, the activator of the classical complement pathway and a key immune system mediator in neuroinflammatory and autoimmune disorders. Unlike existing C1q-targeting approaches that focus on blocking the classical complement pathway, Montis has discovered novel anti-C1q antibodies, capable of targeting C1q’s complement-independent functions with or without inhibiting the classical complement cascade. These antibodies hold the potential to offer a paradigm shift in the complement field and to revolutionize treatments for certain neurodegenerative diseases and autoimmune neuropathies. Based on extensive in vitro end in vivo evaluation, Montis is working on selecting the drug candidates and aims to initiate two Phase 1 clinical trials in these indications in 1H 2026. Montis’ second program (MB02) focuses on inhibiting CD93, a novel perivascular target, in lung squamous cell carcinoma (LUSC). A potent drug candidate was selected, holding best-in-class potential in this inflammation-driven and underserved oncology indication. Montis plans to partner this promising asset. Montis is backed by a strong investor syndicate, including Droia Ventures, Pfizer Ventures, Polaris Innovation Fund, ALSA Ventures and VIB, and is led by a team with extensive drug development experience. Contact: [email protected] Our website is currently in an updating phase.
- Website
-
https://www.montisbio.com/
External link for Montis Biosciences
- Industry
- Biotechnology Research
- Company size
- 2-10 employees
- Headquarters
- Heverlee, Flemish Region
- Type
- Privately Held
- Founded
- 2020
- Specialties
- neuroinflammation, oncology, neurodegeneration, and autoimmune disorders
Locations
-
Primary
Get directions
Bio-Incubator 4 - Gaston Geenslaan 3
Heverlee, Flemish Region 3001, BE
Employees at Montis Biosciences
-
Griet Vanpoucke
Head New Ventures at VIB
-
Iman El-Hariry
Chief Medical Officer and Scientific Advisory Member at Ranok Therapeutics
-
Katrien HEMELAERS
Office & HR Manager - Executive Assistant to the CEO at Montis Biosciences
-
Andrea Casazza
Director Translational Science at Montis Biosciences
Updates
-
During our Q3 Company Breakfast Meeting this morning, our CEO Gil Beyen gave an update to (part of) the team on the latest developments and the outcomes of last week's Board Meeting. Exciting times ahead at Montis Biosciences! Today is unfortunately also the last day of one of our Science Talents' Project Consultants... Thank you Jeroen Vroonen for the past year and good luck in your new project! Mo Benkheil, PhDAndrea Casazza, Ward Celus, Nathan Reynders, Madryn Lake, Celia Luchena Moreno, PhD, Liesbeth Deaulmerie, Soumia Arredouani, Nils Delmouzée, Katrien HEMELAERS
-
-
Montis Biosciences reposted this
📢 We’re thrilled to announce that three of our flanders.bio member companies will be pitching their groundbreaking innovations at the upcoming HealthTech Innovation Days (#HTID6) in Paris on September 17-18! Join us in cheering for: ➡ Montis Biosciences - Gil Beyen at "Pitch Session 2: Biotech" - 17/09 ➡ Amalus Therapeutics - Bart Roman at "Pitch Session 4: Biotech" - 18/09 ➡ Allegro Biotech - Lucas D. (Decuypere) at "Pitch Session 4: Biotech" - 18/09 We are proud to see them represent our vibrant community and contribute to accelerating innovation. 🙌 https://lnkd.in/epNkCjQb ❗ flanders.bio members benefit from a 15% discount on registration fees. Contact us to obtain your discount code. #HealthTech #Innovation #Biotech #HTID2024 - HealthTech For Care
-
-
Montis Biosciences reposted this
Last Thursday, flanders.bio hosted its annual general assembly. As we celebrate our 20th anniversary in 2024, we chose to hold the meeting at the Kasteel van Zwijnaarde, paying homage to the iconic location where it all began in 2004. We were delighted to welcome a select group of members and partners, creating a vibrant mix of quality information, company pitches, and an engaging panel discussion on ecosystem hot topics led by our esteemed flanders.bio board members. The meeting was concluded with a meet and greet during a sunny BBQ. The support for the team’s achievements, plans, and enthusiastic candidate presentations for the 2024 Board elections was heartening. Thank you for that! 🙏 We proudly welcome and reintroduce the following members to our renewed Board of Directors (BOD): 2 Bridge (Ann Meulemans), Montis Biosciences (GIL BEYEN), QbD Group (Bart Van Acker) and PMV (Kenneth W.). Together with all members and partners, we aim to strengthen the biotech and life sciences ecosystem even further! On behalf of the BOD and management, we extend our heartfelt gratitude to our outgoing BOD member etherna (Bernard Sagaert). His years of support and valuable advice have been instrumental to flanders.bio and the entire ecosystem. We assure you that the etherna family will remain close to our life sciences heart. Thank you to all who attended. flanders.bio eagerly anticipates a successful continuation in 2024 and beyond. Wishing you all an excellent summer! ☀️🌿 #ecosystembuilding #biotechnology #lifesciences #health #agrifoodtech #flandersbio #20years #flanders #belgium
-
-
-
-
-
4
-
-
Montis Biosciences reposted this
Scientist in Biosciences │ Cellular & Molecular Biologist │ Neuroscience & Immuno oncology Research │ Research & Development │ Project Management │ Music lover
This week I am attending the #ADPD2024 conference in beautiful Lisbon 😊 Perfect place to learn about the newest discoveries in inflammation and neuropathology of Alzheimer's and Parkinson's disease & hopefully bring back some ideas to Montis Biosciences
-
-
Thank you to our team for an amazing year full of challenges and fun. Enjoy the well-deserved X-mas holidays with your families! 🎄🎅 Liesbeth Deaulmerie Jana Bruyland Inge Betz Nils Delmouzée Jeroen Vroonen Nathan Reynders Madryn Lake Ward Celus Celia Luchena Moreno, PhD Soumia Arredouani Sylvia Ujwary Katrien HEMELAERS Andrea Casazza Mohammed Benkheil, PhD Iman El-Hariry Gil Beyen
-